The endocannabinoid system and bone disease

Stimulation of the endocannabinoid receptors 1 and 2 and the TRPV1 capsaicin receptor downstream modulates bone formation and bone resorption. Bone tissue is maintained homeostatically between osteoclast and osteoblast activity. Studies have shown that CB1 and TRPV1 stimulation elicits osteoclastogenic effects, whereas CB2 stimulation is anti-osteoclastogenic. This would seem to mean that the endocannabinoid system has a role to play in the pathogenesis and potential therapy of osteoporosis. The very same system appears likely as well to have a role to play in bone cancer. Endocannabinoid modulation reduces cell growth and enhances apoptosis, and it also reduces cell invasion and bone pain, at least in mouse models of the disease. The mechanisms underlying these apparent effects need illuminating, but hybrid molecules that target these receptors are a reasonable concept to entertain in research toward future management of bone disease. 

PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis but without residual cannabinoids like THC or any of the impurities or chemicals associated with plant-derived production processes. Our molecular assembly technique, that synthesizes CBD from aromatic terpenes instead of cannabis, assures you the food and pharmaceutical-grade quality that you need for quality-conscious customers. If you are interested in PureForm CBD™ or want to partner on any other of the 140+ known cannabinoids, please contact Damian Peters at310-666-4869, or email info@pureformglobal.com. 

The foregoing is a report on trends and developments in the cannabinoid industry. No product described herein is intended to diagnose, treat, cure or prevent any disease or syndrome.